Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvanted imsapepimut and etimupepimut - IO Biotech

Next Previous
Drug Profile

Adjuvanted imsapepimut and etimupepimut - IO Biotech

Alternative Names: Cylembio; IO102-IO103; PD-L1/IDO peptide vaccine

Latest Information Update: 27 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IO Biotech
  • Developer IO Biotech; Merck & Co
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Bladder cancer; Non-small cell lung cancer; Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse events data from the phase II trial in Malignant melanoma were presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 28 May 2026 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, In the elderly, In adults) in USA (SC)
  • 22 Apr 2026 Efficacy and adverse events data from a phase II trial in Malignant melanoma and Squamous cell cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top